Author:
Overbeek Joanneke K.,Guchelaar Niels A.D.,Mohmaed Ali Ma Ida,Ottevanger Petronella B.,Bloemendal Haiko J.,Koolen Stijn L.W.,Mathijssen Ron H.J.,Boere Ingrid A.,Hamberg Paul,Huitema Alwin D.R.,Sonke Gabe S.,Opdam Frans L.,ter Heine Rob,van Erp Nielka P.
Reference43 articles.
1. Committe for Medicinal Products for Human Use (CHMP) European Medicines Agency (EMA). Summary of product characteristics; Lynparza (olaparib). 2015. Last updated: 02-02-2023.
2. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology;Bruin;Clin Pharmacokinet,2022
3. NCBI ClinicalTrials.gov. Search results 'Olaparib'. Available at: 〈https://beta.clinicaltrials.gov/search?intr=Olaparib〉. Accessed on 12th of June 2023.
4. Effect of Itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies;Dirix;Clin Ther,2016
5. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies;Hellriegel;Clin Pharmacol Ther,1996
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献